Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$3.05 +4.2%	$2.34	$1.60 ▼ $17.55	$82.68M	1.87	385,196 shs	276,114 shs
MCRB Seres Therapeutics	$7.67 +3.1%	$10.30	$6.53 ▼ $30.60	$66.97M	2.89	146,663 shs	69,287 shs
PIRS Pieris Pharmaceuticals	$13.60	$15.17	$6.20 ▼ $18.68	$17.95M	0.61	71,094 shs	51,728 shs
TCRX TScan Therapeutics	$1.38 -4.2%	$1.39	$1.02 ▼ $9.29	$78.10M	1.06	399,615 shs	550,438 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	+2.61%	+20.70%	+31.41%	-8.11%	-76.04%
MCRB Seres Therapeutics	-3.38%	+0.40%	-8.82%	-53.70%	-60.31%
PIRS Pieris Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+24.77%
TCRX TScan Therapeutics	+9.09%	+9.92%	-8.28%	-33.64%	-84.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANRO Alto Neuroscience	1.6983 of 5 stars	3.3	1.0	0.0	0.0	3.1	0.8	0.6
MCRB Seres Therapeutics	3.4542 of 5 stars	2.9	3.0	0.0	4.6	2.8	0.8	0.0
PIRS Pieris Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	3.9626 of 5 stars	4.5	4.0	0.0	0.0	3.0	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANRO Alto Neuroscience	2.57	Moderate Buy	$15.40	404.26% Upside
MCRB Seres Therapeutics	1.80	Reduce	$73.67	860.45% Upside
PIRS Pieris Pharmaceuticals	0.00	N/A	N/A	N/A
TCRX TScan Therapeutics	3.00	Buy	$7.80	465.22% Upside

Current Analyst Ratings Breakdown

Latest PIRS, TCRX, MCRB, and ANRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	ANRO Alto Neuroscience	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$4.00 ➝ $4.00
5/8/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$1.25 ➝ $6.00
5/7/2025	TCRX TScan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $10.00
5/6/2025	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$7.00
4/8/2025	TCRX TScan Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/7/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
3/21/2025	ANRO Alto Neuroscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/20/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
3/14/2025	MCRB Seres Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$20.00 ➝ $15.00
3/14/2025	TCRX TScan Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$10.00
3/7/2025	TCRX TScan Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$14.00 ➝ $3.00

(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	$126.33M	0.53	N/A	N/A	($0.35) per share	-21.91
PIRS Pieris Pharmaceuticals	$42.81M	0.42	N/A	N/A	$21.66 per share	0.63
TCRX TScan Therapeutics	$4.42M	17.66	N/A	N/A	$3.15 per share	0.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANRO Alto Neuroscience	-$36.31M	-$2.34	N/A	N/A	N/A	N/A	-49.28%	-33.52%	N/A
MCRB Seres Therapeutics	-$113.72M	-$4.60	N/A	N/A	N/A	N/A	N/A	-55.08%	N/A
PIRS Pieris Pharmaceuticals	-$24.54M	-$12.10	N/A	∞	N/A	-39.71%	-80.93%	-59.55%	N/A
TCRX TScan Therapeutics	-$89.22M	-$1.09	N/A	N/A	N/A	-1,188.88%	-58.72%	-36.02%	8/11/2025 (Estimated)

Latest PIRS, TCRX, MCRB, and ANRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ANRO Alto Neuroscience	-$0.59	-$0.53	+$0.06	-$0.56	N/A	N/A
5/12/2025	Q1 2025	TCRX TScan Therapeutics	-$0.28	-$0.26	+$0.02	-$0.26	$1.62 million	$2.17 million
5/7/2025	Q1 2025	MCRB Seres Therapeutics	-$0.67	-$2.24	-$1.57	$3.75	$10.00 million	N/A
3/20/2025	Q4 2024	ANRO Alto Neuroscience	-$0.65	-$0.56	+$0.09	-$0.56	N/A	N/A
3/5/2025	Q4 2024	TCRX TScan Therapeutics	-$0.27	-$0.29	-$0.02	-$0.30	$1.43 million	$0.67 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
PIRS Pieris Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANRO Alto Neuroscience	0.05	13.10	13.09
MCRB Seres Therapeutics	N/A	1.12	1.12
PIRS Pieris Pharmaceuticals	N/A	4.82	4.82
TCRX TScan Therapeutics	0.13	9.56	9.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANRO Alto Neuroscience	N/A
MCRB Seres Therapeutics	59.34%
PIRS Pieris Pharmaceuticals	40.11%
TCRX TScan Therapeutics	82.83%

Insider Ownership

Company	Insider Ownership
ANRO Alto Neuroscience	11.13%
MCRB Seres Therapeutics	4.70%
PIRS Pieris Pharmaceuticals	6.39%
TCRX TScan Therapeutics	2.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANRO Alto Neuroscience	N/A	27.07 million	N/A	N/A
MCRB Seres Therapeutics	330	8.73 million	162.03 million	Optionable
PIRS Pieris Pharmaceuticals	140	1.32 million	1.24 million	Optionable
TCRX TScan Therapeutics	100	56.59 million	51.90 million	Not Optionable

PIRS, TCRX, MCRB, and ANRO Headlines

Recent News About These Companies

Lynx1 Capital Management Lp Acquires 1,200,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock

May 22 at 7:20 AM | insidertrades.com

Head-To-Head Analysis: TScan Therapeutics (NASDAQ:TCRX) versus Twist Bioscience (NASDAQ:TWST)

May 22 at 1:07 AM | americanbankingnews.com

TScan Therapeutics (NASDAQ:TCRX) Announces Quarterly Earnings Results

May 14, 2025 | marketbeat.com

Equities Analysts Set Expectations for TCRX Q2 Earnings

May 13, 2025 | marketbeat.com

HC Wainwright Issues Optimistic Outlook for TCRX Earnings

May 13, 2025 | americanbankingnews.com

Wedbush Equities Analysts Cut Earnings Estimates for TCRX

May 11, 2025 | marketbeat.com

Research Analysts Issue Forecasts for TCRX Q1 Earnings

May 10, 2025 | marketbeat.com

What Analysts Are Saying About TScan Therapeutics Stock

May 10, 2025 | nasdaq.com

HC Wainwright Has Lowered Expectations for TScan Therapeutics (NASDAQ:TCRX) Stock Price

May 9, 2025 | marketbeat.com

TScan Therapeutics' (TCRX) "Outperform" Rating Reiterated at Wedbush

May 8, 2025 | marketbeat.com

3TCRX : What Analysts Are Saying About TScan Therapeutics Stock

May 7, 2025 | benzinga.com

TScan Therapeutics (TCRX) to Release Earnings on Monday

May 7, 2025 | marketbeat.com

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

May 6, 2025 | zacks.com

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025 | globenewswire.com

TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of "Buy" from Analysts

May 5, 2025 | marketbeat.com

TScan Therapeutics Announces Abstract Acceptance for Poster Presentation at ASGCT 28th Annual Meeting

April 30, 2025 | nasdaq.com

Adage Capital Partners GP L.L.C. Trims Position in TScan Therapeutics, Inc. (NASDAQ:TCRX)

April 30, 2025 | marketbeat.com

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

April 28, 2025 | globenewswire.com

Why TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 9.62%

April 17, 2025 | aaii.com

Needham Sticks to Its Buy Rating for TScan Therapeutics (TCRX)

April 9, 2025 | markets.businessinsider.com

Why TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 17.27%

April 8, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PIRS, TCRX, MCRB, and ANRO Company Descriptions

Alto Neuroscience NYSE:ANRO

$3.05 +0.12 (+4.23%)

Closing price 03:59 PM Eastern

Extended Trading

$3.00 -0.05 (-1.77%)

As of 04:56 PM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Seres Therapeutics NASDAQ:MCRB

$7.67 +0.23 (+3.09%)

Closing price 04:00 PM Eastern

Extended Trading

$7.79 +0.12 (+1.56%)

As of 04:51 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Pieris Pharmaceuticals NASDAQ:PIRS

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.

TScan Therapeutics NASDAQ:TCRX

$1.38 -0.06 (-4.17%)

Closing price 04:00 PM Eastern

Extended Trading

$1.39 +0.01 (+0.65%)

As of 07:28 PM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time